Last reviewed · How we verify
Empagliflozin 25mg
At a glance
| Generic name | Empagliflozin 25mg |
|---|---|
| Also known as | Jardiance, empagliflozin |
| Sponsor | Samuel Lunenfeld Research Institute, Mount Sinai Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SGLT2i, Pioglitazone, and Ketone Production in T2D (PHASE1)
- Ketones, SGLT2, HFrEF (EARLY_PHASE1)
- Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition (PHASE1)
- Use of Empagliflozin to Treat Prediabetes (PHASE4)
- Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study (PHASE4)
- A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) (PHASE4)
- Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg (PHASE1)
- Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Empagliflozin 25mg CI brief — competitive landscape report
- Empagliflozin 25mg updates RSS · CI watch RSS
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital portfolio CI